Eloxx Pharmaceuticals Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$52.5M
Industry:Biotech
Founded:2013
Lead Investor(s):N/A

Industry Ranking

Estimated Revenue & Financials

  • Eloxx Pharmaceuticals's estimated annual revenue is currently $3.3M per year.
  • Eloxx Pharmaceuticals's estimated revenue per employee is $65,100
  • Eloxx Pharmaceuticals's total funding is $52.5M.

Employee Data

  • Eloxx Pharmaceuticals has 50 Employees.
  • Eloxx Pharmaceuticals grew their employee count by 35% last year.
  • Eloxx Pharmaceuticals currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Ultivue
$8.7M56-12%N/AN/A
Ohana Bioscienc...
$8.7M5660%N/AN/A
Compass Therape...
$16.4M10614%N/AN/A
Cell Signaling ...
$89.4M577N/AN/AN/A
Momenta Pharmac...
N/A220N/AN/AN/A
Emulate
$15.3M99-17%N/AN/A
ArQule
N/A94N/AN/AN/A
Hamilton Storag...
$17.2M1119%N/AN/A
Alnylam Pharmac...
$74.9M127731%N/AN/A
Transgenomic
N/A47N/AN/AN/A
Missing a competitor? Contribute!?
Submit

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx's lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.

keywords:N/A

50

Number of Employees

$3.3M

Revenue (est)

1

Current Jobs

35%

Employee Growth %

$52.5M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Executive Contacts

NameTitleEmail
Amy BombardierAssociate Director, Program Management
Greg WilliamsChief Operating Officer
Amy DaigleExecutive Assistant/Office Manager
Daniel CrawfordPrincipal Scientist, Pharmacology And Translational Sciences
Tristan HuVice President, Biometrics
Robert WardChairman And Chief Executive Officer
Sal FiricanoSenior Director, Information Technology
Neil BelloffGeneral Counsel
Rose VillandryVP Human Resources
Kristie KapinasDirector Of Advocacy And Alliances

Eloxx Pharmaceuticals News

09/03/2019 - Eloxx Pharmaceuticals Announces Two Abstracts Accepted ...

Eloxx Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Society of Nephrology (ASN) Kidney Week 2019 ...

08/26/2019 - Eloxx Pharmaceuticals to Participate in the 14th Annual Citi ...

WALTHAM, Mass., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical ...

09/03/2019 - Eloxx Pharmaceuticals (OTCMKTS:ELOX) Stock Rating ...

Eloxx Pharmaceuticals (OTCMKTS:ELOX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report ...

Eloxx Pharmaceuticals Executive Hires

DateNameTitleReference
2017-09-27Gregory WeaverCFOArticle
2017-12-28Robert WardCEO/ChairmanArticle
2018-06-19Neil BelloffEVP, General Counsel & Corporate SecretaryArticle

Eloxx Pharmaceuticals Acquisitions

DateCompany NameAmountNotesReference
2017-12-21Sevion TherapeuticsArticle